arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2006-12-3-212-215arthyper-1068Research ArticleПРИГЛАШЕНИЕ К ДИСКУССИИDISCUSSIONБета-блокаторы в лечении артериальной гипертензии - наступило ли время забвения?Beta-blockers in hypertension treatment - did the time of farewell come?КонрадиА. О.KonradyA. O.noemail@neicon.ruНИИ кардиологии им. В.А.АлмазоваРоссияAlmazov Research Institute of CardiologyRussian Federation200628062006123212215Copyright © Конради А.О., 20062006Конради А.О.Konrady A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1068

В последние два года широко дискутируется вопрос о целесообразности применения бета-блокаторов в качестве первой линии терапии артериальной гипертензии. Однако аргументы в пользу отказа от широкого использования ß-блокаторов получены в основном при применении относительно старых препаратов с большим количеством негативных эффектов, в частности атеполола. Ряд более селективных и современных препаратов, например бетаксолол, не обладают ни отрицательными метаболическими эффектами, ни большинством побочных эффектов терапии ß-блокаторами. Это не позволяет экстраполировать результаты клинических исследований, выполненных с использованием атенолола, на весь класс В-блокаторов.

During the last two years the issue of use of beta-blockers in first line hypertension therapy is debated. Besides, evidence for refuse from wide of these agents is obtained from trials, testing relatively old agents such as atenolol with a number of negative metabolic effects. At the same time, newer representatives of beta-blockers with high selectivity, for example betaxolol do not. produce such adverse effects. This can indicate that the data obtained on atenolol cannot be extrapolated on the whole drug class.

артериальная гипертензиябета-блокаторыбетаксололhypertensionbeta-blockersbetaxololReferencesLindholm L.H., Ibsen T., Dahlof B. Et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE). Lancet 2002; 359; 1004-1010.Lindholm L.H., Ibsen T., Dahlof B. Et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE). Lancet 2002; 359; 1004-1010.Zanchetti A., Bond G., Hennig M, et al: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 42272427.Zanchetti A., Bond G., Hennig M, et al: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 42272427.Dahlof B., Sever P.S., Poulter N.R, et al. Prevention of cardiovascularevents with an antihypertensive regimen of amlodipine addingperindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Dahlof B., Sever P.S., Poulter N.R, et al. Prevention of cardiovascularevents with an antihypertensive regimen of amlodipine addingperindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Lithell H., Pollare T., Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992;.1:92-101.Lithell H., Pollare T., Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992;.1:92-101.Рекомендации пo профилактике, диагностики и лечению артериальной гипертензии. Артериальная гипертензия 2001 том 7. приложение 1.Рекомендации пo профилактике, диагностики и лечению артериальной гипертензии. Артериальная гипертензия 2001 том 7. приложение 1.Lindholm L.H., Carlberg В., Samuelsson О. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 366: 1545-53.Lindholm L.H., Carlberg В., Samuelsson О. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 366: 1545-53.Kaplan N.K., Opie L.N. Controversies in hypertension The Lancet 2006; 367:168-176Kaplan N.K., Opie L.N. Controversies in hypertension The Lancet 2006; 367:168-176Irvine N.A., Lipworth B.J., McDevitt D.G. A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol. Br J Clin Pharmacol. 1990 ;30:119-26Irvine N.A., Lipworth B.J., McDevitt D.G. A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol. Br J Clin Pharmacol. 1990 ;30:119-26Djian, J Clinical evaluation of betaxolol as a once-daily treatment for hypertension in 4685 patients Br J Clm Pract 1985;39:188-191.Djian, J Clinical evaluation of betaxolol as a once-daily treatment for hypertension in 4685 patients Br J Clm Pract 1985;39:188-191.Бытрова M.M., Бриттов A.H., Горбунов Ю.М. с соавторами. Лечение артериальной гипертензии бетаксололом у женщин в постменопаузе. Терапевтический архив.1999;71(6):67-69.Бытрова M.M., Бриттов A.H., Горбунов Ю.М. с соавторами. Лечение артериальной гипертензии бетаксололом у женщин в постменопаузе. Терапевтический архив.1999;71(6):67-69.Jaillard J., Rouffy J., Sauvanet J. et al/ Long-term influence of betaxolol on plasma lipids and lipoproteins. In Morselli et al. L.E.R.S.Monograph. New York, Raven Press; 1983; 221-231.Jaillard J., Rouffy J., Sauvanet J. et al/ Long-term influence of betaxolol on plasma lipids and lipoproteins. In Morselli et al. L.E.R.S.Monograph. New York, Raven Press; 1983; 221-231.Van Os, Van Brummeneisen P., Woitteis A.J.J. Betaxolol on obese hypertensive patients Long-term effects on blood pressure and serum lipids. Neth J Med 1991; 40:227-231.Van Os, Van Brummeneisen P., Woitteis A.J.J. Betaxolol on obese hypertensive patients Long-term effects on blood pressure and serum lipids. Neth J Med 1991; 40:227-231.Hamon P., Bellemin J.P., Cressens J.P. et al. Responses mataboliqies et endocriniennes a l“hyperglycemie et a l“hyperglycemie aiguë chez le volontaire sain recevant du betaxolol. J Am Med Assoc (French edn) 1985 ; 10 Suppl. 99 : 37-40.Hamon P., Bellemin J.P., Cressens J.P. et al. Responses mataboliqies et endocriniennes a l“hyperglycemie et a l“hyperglycemie aiguë chez le volontaire sain recevant du betaxolol. J Am Med Assoc (French edn) 1985 ; 10 Suppl. 99 : 37-40.Davies I., Larribaut J., Thiercelin J. et al. Betaxolol does not modify hypoglycemic actions on glibenclamide or metformine in normal subjects. Br J Clin Pharmacol 1984; 17:622P.Davies I., Larribaut J., Thiercelin J. et al. Betaxolol does not modify hypoglycemic actions on glibenclamide or metformine in normal subjects. Br J Clin Pharmacol 1984; 17:622P.Brugmann U., Blassini R., Rudolph W. et al. Comparative effects of long-acting beta-adrenergic receptor blockers with and without cardioselectivity: double-blind randomized cross-over and placebo-controlled study of betaxolol and nadolol. Circulation 1983; 68:Suppl 111:406.Brugmann U., Blassini R., Rudolph W. et al. Comparative effects of long-acting beta-adrenergic receptor blockers with and without cardioselectivity: double-blind randomized cross-over and placebo-controlled study of betaxolol and nadolol. Circulation 1983; 68:Suppl 111:406.Kilborn J.R., Morseli P.L., Sauders J. et al. The effects of new beta-blocker SL 75212 on the cardiovascular responses to insulin induced hypoglycemia in man. Br J Clin Pharmacol 1979; 8:409P.Kilborn J.R., Morseli P.L., Sauders J. et al. The effects of new beta-blocker SL 75212 on the cardiovascular responses to insulin induced hypoglycemia in man. Br J Clin Pharmacol 1979; 8:409P.Johnson B.F., Whelton A. A Study Design for Comparing the Effects of Missing Daily Doses of Antihypertensive Drugs. Am J Ther. 1994;1:260-267Johnson B.F., Whelton A. A Study Design for Comparing the Effects of Missing Daily Doses of Antihypertensive Drugs. Am J Ther. 1994;1:260-267Lee J.Y., Kusek J.W., Greene P.G., et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. AmJ Hypertens 1996; 9: 719-725.Lee J.Y., Kusek J.W., Greene P.G., et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. AmJ Hypertens 1996; 9: 719-725.Hosie J., Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9:S15-S18.Hosie J., Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9:S15-S18.Kunka R.L., Wong Y.Y., Andersen R.L., Haack D.G. Steady-state fluctuation and variability of betaxolol and atenolol plasma levels. Ther Drug Monit. 1989 Sep;11(5):523-7Kunka R.L., Wong Y.Y., Andersen R.L., Haack D.G. Steady-state fluctuation and variability of betaxolol and atenolol plasma levels. Ther Drug Monit. 1989 Sep;11(5):523-7Dabrowski R., Wozniak J., Kowalik I., Szwed H.Working women are better responders to beta-blocker monotherapy of mild hypertension than men. Int J Clin Pharmacol Res. 2004; 24(4): 123-128.Dabrowski R., Wozniak J., Kowalik I., Szwed H.Working women are better responders to beta-blocker monotherapy of mild hypertension than men. Int J Clin Pharmacol Res. 2004; 24(4): 123-128.Takase B., Abe Y., Nagata M. et al. Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension. Biomed Pharmacother. 2005 Oct;59 Suppl 1.S158-62Takase B., Abe Y., Nagata M. et al. Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension. Biomed Pharmacother. 2005 Oct;59 Suppl 1.S158-62Kobayashi N., Yoshida K., Mita S. Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats. J Hypertens. 2004 Jul;22(7):1397-402.Kobayashi N., Yoshida K., Mita S. Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats. J Hypertens. 2004 Jul;22(7):1397-402.

The authors declare that there are no conflicts of interest present.